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ABSTRACT 
Alzheimer’s disease is one of the most common causes of dementia nowadays, and its 
prevalence increases over time. Because of this, accurate methods for the analysis of 
specific biomarkers for an early diagnosis of this disease are much needed. Recently, 
the levels of unfolded isoform of the multifunctional protein p53 in plasma have been 
proved to increase selectively in Alzheimer’s Disease patients in comparison with 
healthy subjects, thus entering the list of biomarkers that can be used for the diagnosis 
of this illness. 
We present here the development of an electrochemical immunosensor based on 
nanostructured screen-printed carbon electrodes for the quantification of unfolded 
p53 in plasma samples. The sensor shows a suitable linear range (from 2 to 50 nM) for 
its application in real blood samples and a very low limit of detection (0.05 nM). The 
concentration of unfolded p53 has been accurately detected in plasma of elderly 
people in healthy conditions, subjects with mild cognitive impairment (MCI) and 
Alzheimer’s Disease (AD) subjects, obtaining results with no significant differences to 
those provided by an ELISA assay. This result supports the possibility of measuring 
unfolded p53 levels with a cheap, simple and miniaturized device with a promising 
future for point-of-care applications in the early diagnosis of Alzheimer’s dementia. 





































































Nowadays, Alzheimer’s disease (AD) is a major global public health challenges facing 
our society. It is the most common type of dementia (represents 50-75% of all 
dementias). Its prevalence is increasing worldwide: approximately 47 million people 
live with this type of dementia around the world, and this number is projected to 
increase to more than 131 million by 2050 [1–3]. AD is a progressive 
neurodegenerative disorder related to aging: approximately, it is suffered by 1% of 
people between 65 and 69 years old and it is higher than 50% in individuals above 95 
years old [4]. The most characteristic symptoms of AD are difficulties with memory, 
language, problem-solving and other kind of cognitive skills which affect the person’s 
ability to perform daily activities [5]. These symptoms increase with time, and they can 
reflect the degree of damage in human brain. The AD degenerative process may start 
approximately 20 or 30 years before the clinical diagnosis of the disease. Early 
cognitive alterations defining a mild cognitive impairment (MCI) that is not altering 
daily life, may often precede AD dementia, but does not allow the identification of a 
specific type of neurodegenerative disorder [6,7]. 
An accurate and early diagnosis for the AD process would be very important in the 
treatment of the dementia, both in terms of slowing the progress of the disease and 
helping to prepare the patients and their family for the future. There is not a single test 
for the diagnosis of dementia: specialists use different approaches by obtaining 
medical family history, conducting cognitive tests, using brain imaging or blood tests, 
to discard other causes of the symptoms such as tumours or different vitamin 




































































remains a battery of tests for cognitive and behavioural evaluation. Consequently, AD 
cannot be clinically diagnosed until dementia is well established and a definitive 
diagnosis of AD must wait post mortem autoptic brain analysis and the identification of 
the histological changes originally described by Alois Alzheimer [8,9]. Because of this, it 
is increasingly important the identification of different proteins responsible for 
neurodegeneration that could help in the diagnosis and management of AD. This kind 
of proteins, named biological markers or biomarkers, are detectable or measurable 
indicators of different biological processes, pathogenic processes or pharmacological 
responses to therapeutic interventions. They can be found in biological tissues or 
fluids, as blood or cerebrospinal fluid, and their clinical utility is defined by the 
sensitivity, specificity and ease of use [10,11]. In order to be useful for diagnosis, a 
biomarker should be able to differentiate those mild cognitive impairment (MCI) 
patients, still autonomous, who will eventually progress into AD or into a moderate 
dementia due to other factors [12]. 
Nowadays, among all the biomarkers considered useful in routine diagnosis of AD in 
human cerebrospinal fluid (CSF), the most common are tau protein (total tau and 
phosphorylated tau at threonine 181) and amyloid beta 1-42 (Aβ42). Both can reflect 
the neuropathology development and progression in AD and MCI [13–16]. Tau protein 
is a microtubular-associated protein, located in the neuronal axons, that facilitates the 
regulation of the transport of organelles to and from synapses, especially 
mitochondria; its transport is essential for having a correct synaptic function [8,17,18]. 
On the other hand, accumulation of amyloid beta 1-42 into plaques is demonstrated to 
be related with AD [19,20]. Aβ42 is secreted as a result of the proteolytic cleavage by 




































































produces toxic oligomeric species and aggregate forming plaques, affecting the 
neurotrophic and neuroprotective properties of the brain [8,21–23]. The 
determination of the presence in the CSF of both total and phosphorylated tau and 
Aβ42 is currently performed in order to provide further evidence to support the 
diagnosis of AD and the progression from MCI to AD, although the results are often 
inconsistent.  With respect to these two biomarkers, recent work has demonstrated 
the superiority of using neuroimaging by fluorodeoxyglucose (FDG)-positron emission 
tomography (PET) in association with statistical parametrical mapping (SPM) in 
predicting the progression to AD and non-AD dementias [24]; while a 90% accuracy 
prediction of conversion of cognitively normal older subjects to either MCI or AD 
within 2-3 years, has recently been obtained by measuring the plasma concentration 
of 10 lipids [25].  Also, in a very recent study, Preische et al.  [26] have reported that 
levels of the protein neurofilament light chain were decreased in both CSF and blood 
serum of presymptomatic familial Alzheimer’s patients and these changes were 
detectable over 16 years before the onset of disease symptoms, confirming the 
potential usefulness of biomarkers for dementia diagnosis. 
A particularly interesting blood biomarker for AD has been described by Uberti et al. 
[27]. These authors observed that compared to fibroblasts from healthy patients, 
fibroblasts from patients with AD expressed much higher levels of a conformationally 
altered (unfolded) p53 protein (called mutant-like p53) [28]. While p53 is a 
multifunctional protein involved in a large number of biological processes for 
maintaining genomic integrity, and preventing tumoral growth following potentially 
genotoxic stimuli by exhibiting antioxidant activities in order to eliminate oxidative 




































































conformation in the pathogenesis of AD [23,27,32–34] and its potential as useful 
biomarker of the disease. 
Immunofluorescence studies in peripheral blood cells have also helped to differentiate 
one antibody, PAb240, which binds to the primary epitope only accessible in the 
unfolded isoform of the protein [30,35,36] (see Figure S1 in Supporting Information). 
Thus, the use of this PAb240 antibody can allow the detection of conformationally 
altered p53 in patients and correlated to different stages of the disease [37]. 
In this work, it is developed an electrochemical immunosensor based on a gold 
nanostructured screen-printed carbon electrode (SPCE) as transducer and PAb240 as 
selective recognition element for the easy quantification of unfolded p53. The 
biosensor consists in a competitive immunoassay carried out on the SPCEs using the 
enzyme alkaline phosphatase as label and a mixture of 3-indoxyl phosphate with silver 
ions as substrate. Analytical signal is based on the anodic stripping of the enzymatically 
reduced silver (Ag0). The biosensor is successfully applied, for the first time and 
without the need of any dilution, in plasma samples from aging people in cognitive 












































































2.1. Apparatus and electrodes 
Disposable screen-printed carbon electrodes (SPCEs) are provided from Metrohm 
Dropsens. These electrodes are composed by a conventional three-electrode 
configuration, printed on a ceramic substrate: working and auxiliary electrodes are 
made of carbon ink, while the pseudoreference electrode is made of silver. The SPCEs 
are connected to the potentiostat through suitable connectors also purchased from 
Metrohm Dropsens. 
Gold nanostructuration on SPCEs is done with a µStat 8000 potentiostat (Metrohm 
Dropsens), interfaced to a computer system and controlled by DropView 8400 
software. 
Voltammetric measurements are carried out using an ECO Chemie µAutolab type II 
potentiostat/galvanostat (Metrohm Autolab) interfaced to a computer system and 
controlled by the NOVA version 2.1 software. 
All the measurements performed in this paper were carried out at room temperature. 
2.2. Reagents and solutions 
Tris(hydroxymethyl)aminomethane (Trizma® base), magnesium nitrate hexa-hydrate, 
albumin from bovine serum (BSA), silver nitrate (AgNO3) and streptavidin from 
Streptomyces avidinii labelled with alkaline phosphatase (S-AP) were purchased from 




































































(HCl) and nitric acid (HNO3) were obtained from Merck. 3-indoxyl phosphate disodium 
salt was delivered by Biosynth. 
p53 monoclonal antibody (PAb240) was purchased from Thermo Fisher Scientific. 
Unfolded p53 peptide and biotin-conjugated unfolded p53 peptide was synthetized 
and furtherly conjugated with biotin by Abyntek Biopharma. 
All chemical reagents used in experiments were of analytical grade and used without 
further purification. Ultrapure water (18.2 MΩ), obtained from a Millipore Direct-Q® 3 
UV purification system from Millipore Ibérica S.A, was used throughout all the work. 
Working solutions of PAb240 monoclonal antibody, BSA, unfolded p53 peptide, 
unfolded-p53 peptide labelled with biotin (p53-bio) and S-AP were prepared in 0.1 M 
Tris-HNO3 buffer, pH 7.2 (buffer 1). Working solutions of 3-IP and AgNO3 were 
prepared in 0.1 M Tris-HNO3 pH 9.8 buffer containing 2 mM Mg(NO3)2 (buffer 2) and 
stored protected from light. Buffer solutions are prepared every week and stored and 
4 °C, whereas working solutions needed for the immunoassay were prepared daily. 
2.3. Procedures 
2.3.1. SPCEs nanostructuration 
Gold nanostructures are in situ generated onto the working electrode by 
electrochemical reduction of AuCl4
- following a method previously optimized by our 
research group [38]. The procedure consists in depositing an aliquot (40 µL) of 1 mM 
HAuCl4 solution (in 0.1 M HCl) on the electrode surface (covering the three electrodes) 
and applying a constant current intensity of -100 µA during 180 s. This leads to the 
formation of nanostructures on the working electrode covering it with monodisperse 




































































washed with ultrapure water and they are ready for use. This procedure for gold 
nanostructuration is performed at room temperature and, using the µStat 8000 
potentiostat, it can be performed in eight different SPCEs at the same time. 
2.3.2. Calibration of the immunosensor for the detection of the unfolded p53 
peptide 
A scheme of the different steps of the biosensor can be seen in Figure 1. With this 
design, different optimizations (concentration of antibody, labelled peptide or bovine 
serum albumin for the blocking step) have been done. The following procedure (Figure 
1) describes an optimized assay. 
The working area of the nanostructured SPCE (AuNP-SPCE) is functionalised by physical 
adsorption coating it with 10 µL of 4 µg mL-1 PAb240 antibody solution and incubating 
overnight, protected from light, at 4 °C. The non-adsorbed antibodies are removed 
rinsing the electrode with buffer 1 and then, the antibody–free surface sites are 
blocked with 40 µL BSA solution (2%) for 30 min. The electrode is washed again using 
buffer 1 and a 40-µL drop of unfolded p53 peptide of varying concentrations is added 
and left to react with the antibody for 1 hour. After a washing step with buffer 1 an 
aliquot of 40 µL of the biotinylated p53 peptide in a fixed concentration (10 nM) is 
deposited and let it react for 1 hour. In this step, all the antibodies that did not react 
with free p53 peptide before, reacted with the biotinylated p53 peptide. Then, the 
electrode is rinsed with buffer 1 and 40 µL of S-AP of a fixed concentration (0.5 nM) is 
added. 
After a washing step with buffer 2, the enzymatic reaction is carried out depositing on 




































































The enzymatic reaction takes place during 20 min, and, after that, a linear sweep 
voltammetry is recorded, from -0.1 V to + 0.4 V at a scan rate of 50 mV s-1. 
2.3.3. Real sample analysis 
The determination of unfolded p53 in blood samples was performed substituting, in 
the immunoassay protocol, the addition of the unfolded p53 peptide standard solution 
by the addition of the sample, in this case, blood plasma. Samples were kindly 
provided by the Unit of Neurology of the Alvarez-Buylla Hospital (Mieres, Asturias, 
Spain) and the Unit of Neurology of Cabueñes Hospital (Gijón, Asturias, Spain). A total 
of 12 plasma samples were tested: 4 cognitively healthy subjects (CHS), 4 patients with 
MCI and 4 patients with AD. Subjects received a diagnosis of AD according to 
NINCDS/ADRDA criteria [39], while MCI diagnosis followed the criteria of Petersen: 
there has to be evidence of memory impairment, preservation of general cognitive and 
functional abilities and absence of any diagnosed dementia [40]. Healthy subjects were 
recruited from routine controls and had to meet the following criteria: i) no history of 
past or current psychiatric or neurologic disorders and ii) a score higher than 26 in the 
Mini-Mental State Examination (MMSE). All patients had undergone neuroimaging and 
neuropsychological assessment, and, depending on their specific clinical profile, other 
personalized tests were also performed. All of them (or their relatives) provided 
written consent for the participation in all the studies and were included in a previous 
study [41]. Blood samples have been processed as indicated by Arce-Varas et al. [41]:. 
plasma is obtained by Ficoll-Hypaque density gradient centrifugation and then 
aliquoted and stored at -80 0C. 




































































3.1. Optimization of experimental conditions 
A heterogeneous competitive immunoassay is adopted to construct the specific 
biosensor for the detection of unfolded p53. As transducer, SPCEs modified with 
electrogenerated gold nanoparticles are used since they have previously demonstrated 
better sensitivity than non-nanostructured SPCEs when bioassays using AP as label and 
mixture of 3-IP/Ag+ as substrate [42]. Moreover, these AuNP-SPCEs allow to develop 
single-use sensors (as the one here developed) due to their low-cost, portability and 
small size, being excellent for the development of point-of-care (POC) devices. 
In order to achieve a selective immunosensor, the PAb240 antibody (capture antibody) 
is immobilized onto the AuNP-SPCE. The competitive immunoreaction is performed in 
two steps in order to increase the sensitivity: first, the sample is added on the AuNP-
SPCE functionalised with the capture antibody in a way the antigen (unfolded p53) 
present in the sample reacts with the antibody; then, the p53-bio (p53 peptide labelled 
with biotin) is added to react with all the free antibodies (i.e. all the antibodies that 
were not occupied with unfolded p53 present in the sample). Thus, the higher the 
amount of unfolded p53 present in the sample, the lower the amount of p53-bio 
reacts with capture antibody and therefore, the lower the analytical signal. 
To trace the immunoassay, the p53-bio is made to react with S-AP because of the 
strong non-covalent interaction that the system streptavidin-biotin provides. In this 
way, the enzyme AP is used as label and the mixture 3-IP/silver nitrate as enzymatic 
substrate. The silver enzymatic deposition catalysed by AP has been previously 
reported by our research group [43]. In the enzymatic reaction, AP hydrolyses 3-IP, 




































































in the solution to metallic silver (Ag0) and indigo blue. By this way, the enzymatically 
generated metallic silver is deposited on the surface of the electrode, and it can be 
detected by performing an anodic stripping scan and measuring the redissolution 
peak. The intensity current of this anodic peak is directly proportional to the 
concentration of p53-bio and therefore, inversely proportional to the concentration of 
unfolded p53 in the sample. 
In order to achieve the best analytical features for the biosensor, experimental 
variables that affect its performance are optimized: i) the concentration of the blocking 
agent, ii) the concentration of the antibody PAb240 and iii) the concentration of p53-
bio. 
Blocking agent. Bovine serum albumin (BSA) is used as a blocking agent to avoid non-
specific binding of proteins onto the surface of the electrode. Concentrations of BSA 
ranging from 1% to 3% are tested in experiments using fixed concentrations of PAb240 
antibody (4 µg mL-1) and of p53-bio (10 nM). As shown in Figure 2, the use of BSA 
increases the signal-to-background ratio significantly, obtaining a maximum when 2% 
BSA is used. Based on these results, this concentration of BSA is used as blocking agent 
in the following steps of the biosensor construction. 
Polyclonal antibody PAb240.  Optimization of the concentration of the antibody 
PAb240 remains a key parameter, as too high amounts of the antibody reacting with a 
low concentrations of the unfolded p53 results in non-detectable analytical signals 
since there is enough antibody to react with the unfolded p53 present in the sample 
and with the bio-p53 added to obtain the signal. Therefore, it is important to make 




































































the AuNP-SPCE in order to cause significant changes in the analytical signal in the case 
of different concentrations of unfolded p53 and therefore, low concentrations could 
be detected. Accordingly, different concentrations of PAb240 antibody are tested, and 
the results obtained are shown in Figure 3. 
 
As can be seen, the highest analytical signal is obtained at a PAb240 antibody 
concentration of 4 µg mL-1, while the background signal remained at low levels at all 
PAb240 concentrations (0-5 µg mL-1) tested.  
Biotin-conjugate p53 peptide. Different amounts of the biotin-conjugate p53 peptide 
are tested in order to establish the experimental conditions providing the highest 
efficiency of this electrochemical immunosensor. As seen in Figure 4, the highest peak 
current intensity signal values correspond to bio-p53 concentrations of 50 nM and 100 
nM. However, 10 nM is finally chosen as the optimum concentration of the bio-p53 
because it consistently provides the signal with the best reproducibility, as error bars 
show. In addition, this is the highest concentration of the bio-p53 tested without 
saturating the electrode surface (Figure 4). 
3.2. Analytical characteristics of the immunosensor 
After the optimization of the main parameters involved in the design of the 
immunosensor, a calibration plot has to be carried out in order to know whether the 
immunosensor responds to increasing concentrations of the p53 peptide. The 
biosensor response against unfolded p53 concentrations between 2 and 50 nM can be 




































































voltammetric peaks (Figure 5A), and it is adjusted into a linear relationship (Figure 5B) 
within that range according to the following equation: 
    
  
                            
The correlation coefficient obtained is 0.997 when measuring unfolded p53 
concentrations in the range between 2 and 50 nM. The limit of detection (LOD) and 
the limit of quantification (LOQ), calculated as 3 or 10 times the standard deviation of 
the intercept divided by the slope are found to be 0.05 and 0.2 nM, respectively. These 
and other figures of merit are summarized in Table S1 (in Supporting Information). 
In order to evaluate the reproducibility of this immunosensor, several biosensors are 
prepared in three different days and with different solutions of all the reagents, 
including the buffer solutions. As illustrated in Table S2 (in Supporting Information), 
the biosensor shows a very good reproducibility, with relative standard deviations 
(RSD) for three different concentrations of unfolded p53 (2, 10 and 50 nM) between 
6.2% and 8.7%. 
3.3. Real samples measurement 
The developed immunosensor is applied to determine the concentration of unfolded 
p53 in real plasma samples from patients who had been diagnosed with MCI or AD as 
well as from control subjects. There is no need for plasma dilution because p53 
concentration in blood samples is within the calibration range of this biosensor, and 
blood plasma does not affect the sensitivity of the sensor.  Samples have been 




































































Values of unfolded p53 peptide levels obtained with the immunosensor are 
summarized in Table 1. For comparison, values for unfolded p53 determined in the 
same samples using direct Enzyme-Linked Immunosorbent Assay (ELISA) [41] are also 
reported. The values of unfolded p53 obtained with the immunosensor and the ELISA 
assay are very similar for all the samples tested with relative errors of below 8% in all 
the cases. 
This confirms the usefulness of the developed immunosensor for the accurate 
detection of unfolded p53 in real samples. Therefore, this sensor offers a simple, 
miniaturized and cost-effective system for selective unfolded p53 quantification with 
the required sensitivity for its use in clinical samples. 
As unfolded p53 is still an emerging biomarker for AD recently suggested, at present, 
there are not established cut-off values to discriminate between healthy, MCI and AD 
subjects. However, the results provided by the sensor, in agreement with previous 
clinical studies [6,27,28,33,37,41], show a clear tendency towards high amounts of 
unfolded p53 in plasma of MCI and AD patients when compared  with plasma from 
control subjects. This increasing amount of unfolded p53 protein in AD subjects can be 
explained considering a higher pro-oxidant intracellular environment, which favours 
the formation of unfolded p53 [29,31]. 
To the best of our knowledge, this is the first biosensor for the quantification of 
unfolded p53 protein, which is a promising biomarker for the diagnosis of AD. 
Moreover, this sensor allows the quantification of unfolded p53 directly in human 
plasma without sample dilution. Other types of p53 protein biosensors can be found in 




































































distinguish between unfolded p53 from the “total”. The biosensor here developed 
offers excellent figures of merit (as can be seen in Table S2 in Supporting Information) 
and has demonstrated great features for the quantification of unfolded p53 in plasma, 




In this work, we have developed a competitive immunosensor based on gold 
nanostructured screen-printed carbon electrodes for the quantification of unfolded 
p53 protein. In order to construct a selective sensor, a monoclonal antibody that only 
reacts with the unfolded isoform of the protein (whose concentration is higher in 
Alzheimer’s Disease patients) has been employed as capture antibody. After the 
optimization of different parameters, a calibration curve has been obtained with 
excellent analytical characteristics (sensitivity, limit of detection and reproducibility). 
The developed sensor allowed measuring the unfolded p53 concentration in plasma 
samples from either patients with different neurodegenerative disorders (mild 
cognitive impairment or Alzheimer’s Disease) or healthy patients with great accuracy. 
It is worthy to highlight that the sensor is able to directly quantify the unfolded p53 in 
plasma without dilution. Hence, the developed biosensor is a low-cost, simple, 
miniaturized and portable device that requires small amounts of sample; thus, it is a 
useful tool for decentralized unfolded p53 analysis contributing to future point-of-care 
applications that could help to the non-invasive diagnosis and monitoring of the 





































































This work has been supported by the FC-15-GRUPIN14-021 project from the Asturias 
Regional Government and the CTQ2014-58826-R and MINECO-18-CTQ2017-86994-R 
projects from the Spanish Ministry of Economy and Competitiveness (MINECO). O. 
Amor-Gutiérrez thanks Vicerrectorado de Investigación from University of Oviedo for 
the award of a grant “Ayudas para la realización de tesis doctorales” (PAPI-18-PF-13) 
through Plan de Apoyo y Promoción de la Investigación. 
SUPPLEMENTARY MATERIAL 
Supplementary data associated with this article can be found in the online version. 
REFERENCES 
[1] P. Scheltens, K. Blennow, M.M.B. Breteler, B. de Strooper, G.B. Frisoni, S. 
Salloway, W.M. Van der Flier, Alzheimer’s disease, Lancet. Neurol. 388 (2016) 
505–517. doi:10.1016/j.med.2019.03.012. 
[2] M. Prince, A. Comas-Herrera, M. Knapp, M. Guerchet, M. Karagiannidou, World 
Alzheimer Report 2016: improving healthcare for people living with dementia, 
2016. doi:10.13140/RG.2.2.22580.04483. 
[3] A. Atri, The Alzheimer’s Disease Clinical Spectrum: Diagnosis and Management, 
Med. Clin. North Am. 103 (2019) 263–293. doi:10.1016/j.mcna.2018.10.009. 
[4] M. Racchi, D. Uberti, S. Govoni, M. Memo, C. Lanni, S. Vasto, G. Candore, C. 
Caruso, L. Romeo, G. Scapagnini, Alzheimer’s disease: new diagnostic and 
therapeutic tools, Immun. Ageing. 5 (2008) 7–11. doi:10.1186/1742-4933-5-7. 
[5] Alzheimer’s Association, 2018 Alzheimer’s disease facts and figures, Alzheimer’s 
Dement. 14 (2018) 367–429. doi:10.1016/j.jalz.2016.03.001. 
[6] C. Lanni, M. Racchi, S. Stanga, G. Mazzini, A. Ranzenigo, R. Polotti, M. Memo, S. 
Govoni, D. Uberti, Unfolded p53 in blood as a predictive signature of the 
transition from mild cognitive impairment to Alzheimer’s disease, J. Alzheimer’s 




































































[7] G. Peng, J. Wang, Z. Feng, P. Liu, Y. Zhang, F. He, Z. Chen, K. Zhao, B. Luo, Clinical 
and neuroimaging differences between posterior cortical atrophy and typical 
amnestic Alzheimer’s disease patients at an early disease stage, Sci. Rep. 6 
(2016) 1–11. doi:10.1038/srep29372. 
[8] K. Blennow, Cerebrospinal fluid protein biomarkers for Alzheimer’s Disease, J. 
Am. Soc. Exp. Neurother. 1 (2004) 213–225. doi:10.3233/JAD-2009-1177. 
[9] H. Hippius, G. Neundörfer, The discovery of Alzheimer’s disease, Dialogues Clin. 
Neurosci. 5 (2003) 101–108. doi:10.1145/1658550.1658558. 
[10] M. Sjögren, N. Andreasen, K. Blennow, Advances in the detection of Alzheimer’s 
disease - use of cerebrospinal fluid biomarkers, Clin. Chim. Acta. 332 (2003) 1–
10. doi:10.1016/S0009-8981(03)00121-9. 
[11] C. Humpel, Identifying and validating biomarkers for Alzheimer’s disease, Trends 
Biotechnol. 29 (2011) 26–32. doi:10.1016/j.tibtech.2010.09.007. 
[12] M. Degerman Gunnarsson, M. Ingelsson, K. Blennow, H. Basun, L. Lannfelt, L. 
Kilander, High tau levels in cerebrospinal fluid predict nursing home placement 
and rapid progression in Alzheimer’s disease, Alzheimer’s Res. Ther. 8 (2016) 
22–31. doi:10.1186/s13195-016-0191-0. 
[13] B. Shui, D. Tao, A. Florea, J. Cheng, Q. Zhao, Y. Gu, W. Li, N. Jaffrezic-Renault, Y. 
Mei, Z. Guo, Biosensors for Alzheimer’s disease biomarker detection: A review, 
Biochimie. 147 (2018) 13–24. doi:10.1016/j.biochi.2017.12.015. 
[14] N. El Kadmiri, N. Said, I. Slassi, B. El Moutawakil, S. Nadifi, Biomarkers for 
Alzheimer Disease: Classical and novel candidates’ review, Neuroscience. 370 
(2018) 181–190. doi:10.1016/j.neuroscience.2017.07.017. 
[15] R. Sangubotla, J. Kim, Recent trends in analytical approaches for detecting 
neurotransmitters in Alzheimer’s disease, Trends Anal. Chem. 105 (2018) 240–
250. doi:10.1016/j.trac.2018.05.014. 
[16] B. Olsson, R. Lautner, U. Andreasson, A. Öhrfelt, E. Portelius, M. Bjerke, M. 




































































H. Zetterberg, CSF and blood biomarkers for the diagnosis of Alzheimer’s 
disease: a systematic review and meta-analysis, Lancet. Neurol. 15 (2016) 673–
684. doi:10.1016/S1474-4422(16)00070-3. 
[17] C. Tapia-Rojas, F. Cabezas-Opazo, C.A. Deaton, E.H. Vergara, G.V.W. Johnson, 
R.A. Quintanilla, It’s all about tau, Prog. Neurobiol. 175 (2019) 54–76. 
doi:10.1016/j.pneurobio.2018.12.005. 
[18] A.M. Pooler, W. Noble, D.P. Hanger, A role for tau at the synapse in Alzheimer’s 
disease pathogenesis, Neuropharmacology. 76 (2014) 1–8. 
doi:10.1016/j.neuropharm.2013.09.018. 
[19] T.L. Spires-Jones, B.T. Hyman, The Intersection of Amyloid Beta and Tau at 
Synapses in Alzheimer’s Disease, Neuron. 82 (2014) 756–771. 
doi:10.1016/j.neuron.2014.05.004. 
[20] A. Kaushik, R.D. Jayant, S. Tiwari, A. Vashist, M. Nair, Nano-biosensors to detect 
beta-amyloid for Alzheimer’s disease management, Biosens. Bioelectron. 80 
(2016) 273–287. doi:10.1016/j.bios.2016.01.065. 
[21] T. Hu, C. Chen, G. Huang, X. Yang, Antibody modified-silver nanoparticles for 
colorimetric immuno sensing of Aβ(1-40/1-42) based on the interaction 
between β-amyloid and Cu2+, Sensors Actuators, B Chem. 234 (2016) 63–69. 
doi:10.1016/j.snb.2016.04.159. 
[22] S. Claeysen, J. Bockaert, P. Giannoni, Serotonin: A New Hope in Alzheimer’s 
Disease?, ACS Chem. Neurosci. 6 (2015) 940–943. 
doi:10.1021/acschemneuro.5b00135. 
[23] D. Uberti, G. Ferrari-Toninelli, S.A. Bonini, I. Sarnico, M. Benarese, M. Pizzi, L. 
Benussi, R. Ghidoni, G. Binetti, P.F. Spano, F. Facchetti, M. Memo, Blockade of 
the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 
prevents β-amyloid neurotoxicity, Neuropsychopharmacology. 32 (2007) 872–
880. doi:10.1038/sj.npp.1301185. 
[24] S.P. Caminiti, T. Ballarini, A. Sala, C. Cerami, L. Presotto, R. Santangelo, F. 




































































Parnetti, P. Eusebi, G. Frisoni, F. Nobili, A. Picco, E. Scarpini, FDG-PET and CSF 
biomarker accuracy in prediction of conversion to different dementias in a large 
multicentre MCI cohort, NeuroImage Clin. 18 (2018) 167–177. 
doi:10.1016/j.nicl.2018.01.019. 
[25] M. Mapstone, A.K. Cheema, M.S. Fiandaca, X. Zhong, T.R. Mhyre, L.H. 
Macarthur, W.J. Hall, S.G. Fisher, D.R. Peterson, J.M. Haley, M.D. Nazar, S.A. 
Rich, D.J. Berlau, C.B. Peltz, M.T. Tan, C.H. Kawas, H.J. Federoff, Plasma 
phospholipids identify antecedent memory impairment in older adults, Nat. 
Med. 20 (2014) 415–418. doi:10.1038/nm.3466. 
[26] O. Preische, S.A. Schultz, A. Apel, J. Kuhle, S.A. Kaeser, C. Barro, S. Gräber, E. 
Kuder-Buletta, C. LaFougere, C. Laske, J. Vöglein, J. Levin, C.L. Masters, R. 
Martins, P.R. Schofield, M.N. Rossor, N.R. Graff-Radford, S. Salloway, B. Ghetti, 
J.M. Ringman, J.M. Noble, J. Chhatwal, A.M. Goate, T.L.S. Benzinger, J.C. Morris, 
R.J. Bateman, G. Wang, A.M. Fagan, E.M. McDade, B.A. Gordon, M. Jucker, 
Dominantly Inherited Alzheimer Network, Serum neurofilament dynamics 
predicts neurodegeneration and clinical progression in presymptomatic 
Alzheimer’s disease, Nat. Med. 25 (2019) 277–283. doi:10.1038/s41591-018-
0304-3. 
[27] C. Lanni, D. Uberti, M. Racchi, S. Govoni, M. Memo, Unfolded p53: A potential 
biomarker for Alzheimer’s disease, J. Alzheimer’s Dis. 12 (2007) 93–99. 
doi:10.3233/JAD-2007-12109. 
[28] D. Uberti, C. Lanni, T. Carsana, S. Francisconi, C. Missale, M. Racchi, S. Govoni, 
M. Memo, Identification of a mutant-like conformation of p53 in fibroblasts 
from sporadic Alzheimer’s disease patients, Neurobiol. Aging. 27 (2006) 1193–
1201. doi:10.1016/j.neurobiolaging.2005.06.013. 
[29] S. Calmels, P. Hainaut, H. Ohshima, Nitric oxide induces conformational and 
functional modifications of wild-type p53 tumor supressor protein, Cancer Res. 
57 (1997) 3365–3369. 
[30] C. Méplan, M.J. Richard, P. Hainaut, Redox signalling and transition metals in the 





































































[31] D. Liu, Y. Xu, p53, Oxidative Stress, and Aging, Antioxid. Redox Signal. 15 (2011) 
1669–1678. doi:10.1089/ars.2010.3644. 
[32] L. Buizza, C. Prandelli, S.A. Bonini, A. Delbarba, G. Cenini, C. Lanni, E. Buoso, M. 
Racchi, S. Govoni, M. Memo, D. Uberti, Conformational altered p53 affects 
neuronal function: Relevance for the response to toxic insult and growth-
associated protein 43 expression, Cell Death Dis. 4 (2013) e484. 
doi:10.1038/cddis.2013.13. 
[33] C. Lanni, M. Racchi, G. Mazzini, A. Ranzenigo, R. Polotti, E. Sinforiani, L. Olivari, 
M. Barcikowska, M. Styczynska, J. Kuznicki, A. Szybinska, S. Govoni, M. Memo, D. 
Uberti, Conformationally altered p53: A novel Alzheimer’s disease marker?, Mol. 
Psychiatry. 13 (2008) 641–647. doi:10.1038/sj.mp.4002060. 
[34] S. Stanga, C. Lanni, S. Govoni, D. Uberti, G. D’Orazi, M. Racchi, Unfolded p53 in 
the pathogenesis of Alzheimer’s disease: Is HIPK2 the link?, Aging (Albany. NY). 2 
(2010) 545–554. doi:10.18632/aging.100205. 
[35] K.G. Wiman, K.P. Magnusson, T. Ramqvist, G. Klein, Mutant p53 detected in a 
majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240, 
Oncogene. 6 (1991) 1633–1639. 
[36] J.V. Gannon, R. Greaves, R. Iggo, D.P. Lane, Activating mutations in p53 produce 
a common conformational effect. A monoclonal antibody specific for the mutant 
form, EMBO J. 9 (1990) 1595–1602. doi:10.1002/j.1460-2075.1990.tb08279.x. 
[37] L. Buizza, G. Cenini, C. Lanni, G. Ferrari-Toninelli, C. Prandelli, S. Govoni, E. 
Buoso, M. Racchi, M. Barcikowska, M. Styczynska, A. Szybinska, D.A. Butterfield, 
M. Memo, D. Uberti, Conformational Altered p53 as an Early Marker of 
Oxidative Stress in Alzheimer’s Disease, PLoS One. 7 (2012) 1–11. 
doi:10.1371/journal.pone.0029789. 
[38] G. Martínez-Paredes, M.B. González-García, A. Costa-García, In situ 
electrochemical generation of gold nanostructured screen-printed carbon 




































































Electrochim. Acta. 54 (2009) 4801–4808. doi:10.1016/j.electacta.2009.03.085. 
[39] G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E.M. Stadlan, 
Clinical diagnosis of Alzheimer’s Disease: report of the NINCDS-ADRDA work 
group under the auspices of Department of Health and Human Services Task 
Force on Alzheimer’s Disease, Neurology. 34 (1984) 939–944. 
[40] R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, E. Kokmen, Mild 
cognitive impairment: clinical characterization and outcome, Arch. Neurol. 56 
(1999) 303–308. doi:http://dx.doi.org/10.1212/01.CON.0000429175.29601.97. 
[41] N. Arce-Varas, G. Abate, C. Prandelli, C. Martínez, F. Cuetos, M. Menéndez, M. 
Marziano, D. Cabrera-García, M. Fernández-Sánchez, A. Novelli, M. Memo, D. 
Uberti, Comparison of Extracellular and Intracellular Blood Compartments 
Highlights Redox Alterations in Alzheimer’s and Mild Cognitive Impairment 
Patients, Curr. Alzheimer Res. 14 (2016) 112–122. 
doi:10.2174/1567205013666161010125413. 
[42] E.C. Rama, M.B. González-García, A. Costa-García, Competitive electrochemical 
immunosensor for amyloid-beta 1-42 detection based on gold nanostructurated 
Screen-Printed Carbon Electrodes, Sensors Actuators, B Chem. 201 (2014) 567–
571. doi:10.1016/j.snb.2014.05.044. 
[43] P. Fanjul-Bolado, D. Hernández-Santos, M.B. González-García, A. Costa-García, 
Alkaline phosphatase-catalyzed silver deposition for electrochemical detection, 
Anal. Chem. 79 (2007) 5272–5277. doi:10.1021/ac070624o. 
[44] H. Fayazfar, A. Afshar, M. Dolati, A. Dolati, DNA impedance biosensor for 
detection of cancer, TP53 gene mutation, based on gold nanoparticles/aligned 
carbon nanotubes modified electrode, Anal. Chim. Acta. 836 (2014) 34–44. 
doi:10.1016/j.aca.2014.05.029. 
[45] M. Pedrero, F.J.M. De Villena, C. Muñoz-San Martín, S. Campuzano, M. 
Garranzo-Asensio, R. Barderas, J.M. Pingarrón, Disposable Amperometric 
Immunosensor for the Determination of Human P53 Protein in Cell Lysates 





































































[46] H. Afsharan, B. Khalilzadeh, H. Tajalli, M. Mollabashi, F. Navaeipour, M.-R. 
Rashidi, A sandwich type immunosensor for ultrasensitive electrochemical 
quantification of p53 protein based on gold nanoparticles/graphene oxide, 





































































CAPTION OF FIGURES 
Figure 1. Scheme of the immunosensing strategy for the detection of unfolded p53. 
 
Figure 2. Effect of the BSA concentration in the peak current intensities obtained with 
the immunosensor in the absence and presence of p53 peptide (10 nM). Experimental 
conditions: PAb240 antibody 4 µg mL-1, p53-biotin-conjugated peptide 10 nM, S-AP 0.5 
nM, 3-IP 0.5 mM, Ag+ 0.2 mM. Data are given as average ± SD (n = 3). 
 
Figure 3. Effect of the PAb240 antibody (capture antibody) concentration in the peak 
current intensities obtained with the immunosensor in the absence and presence of 
p53 peptide (10 nM). Experimental conditions: BSA 2%, PAb240 antibody 4 µg mL-1, S-
AP 0.5 nM, 3-IP 0.5 mM, Ag+ 0.2 mM. Data are given as average ± SD (n = 3). 
 
Figure 4. Effect of the biotin-conjugate p53 peptide concentration in the peak current 
intensities. Experimental conditions: BSA 2%, PAb240 antibody 4 µg mL-1, S-AP 0.5 nM, 
3-IP 0.5 mM, Ag+ 0.2 mM. Data are given as average ± SD (n = 3). 
 
Figure 5. A) Linear sweep voltammograms recorded for different p53 peptide 
concentrations (up to down: 0, 2, 3, 4, 5, 6, 8, 10, 15, 20, 30, 40 and 50 nM) obtained 
with the immunosensor. B) Calibration plot of the immunosensor. Experimental 
conditions: BSA 2%, PAb240 antibody 4 µg mL-1, p53-biotin-conjugated peptide 10 nM, 










































































Table 1. Comparison of the unfolded p53 concentration values obtained using the 
biosensor here described and the ELISA, for real plasma samples from CHS (Control 
Healthy Subjects), MCI (Mild Cognitive Impairment) and AD (Alzheimer’s Disease) 
patients. Data are given as average ± SD (n=3). 
Sample 






CHS1 5.0 ± 0.8 4.98 -0.1 
CHS2 5.6 ± 0.3  5.75 1.9 
CHS3 4.9 ± 0.5  5.01 1.2 
CHS4 5.5 ± 1.0  5.93 7.9 
MCI1 7.6 ± 0.4 7.96 4.8 
MCI2 3.7 ± 0.5  3.86 4.1 
MCI3 4.8 ± 0.4  5.02 3.4 
MCI4 5.2 ± 2.1 5.07 -2.1 
AD1 6.0 ± 0.7  6.34 5.6 
AD2 8.5 ± 0.8  9.05 5.9 
AD3 9.3 ± 0.8  9.76 4.8 
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